Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results

被引：3

作者：

Hess, Georg ^{[1
]}

Karola, Wagner ^{[2
]}

LaRosee, Paul ^{[3
]}

Keller, Ulrich ^{[4
]}

Atta, Johannes ^{[5
]}

Witzens-Harig, Mathias ^{[6
]}

Crombe, Anne ^{[7
]}

Medler, Christoph ^{[8
]}

Borchmann, Peter ^{[9
,10
]}

Bitz, Ulrich ^{[11
]}

Lerchenmuller, Christian ^{[12
]}

Theobald, Matthias ^{[1
]}

Dreyling, Martin H. ^{[13
]}

机构：

[1] Johannes Gutenberg Univ Med Ctr, III Dept Med, Mainz, Germany

[2] Charite, Gerlingen, Germany

[3] Jena Univ Hosp, Jena, Germany

[4] Tech Univ Munich, Munich, Germany

[5] Goethe Univ Frankfurt, Frankfurt, Germany

[6] Univ Heidelberg Hosp, Dept Internal Med V, Heidelberg, Germany

[7] Univ Mainz Hosp, Interdisciplinary Ctr Clin Trials IZKS, Mainz, Germany

[8] IZKS, Mainz, Germany

[9] Univ Hosp Cologne, Dept I Internal Med, Cologne, Germany

[10] Univ Hosp Cologne, German Hodgkin Study Grp GHSG, Cologne, Germany

[11] HELIOS Klin Bad Saarow, Bad Saarow Pieskow, Germany

[12] Outpatient Clin, Hematol & Oncol, Munster, Germany

[13] Univ Hosp Grosshadern LMU, Dept Med III, Munich, Germany

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.2977.2977

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2977

引用

页数：4

共 50 条

[1] Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
Hess, Georg
Wagner, Karola
Keller, Ulrich
La Rosee, Paul
Atta, Johannes
Huebel, Kai
Lerchenmueller, Christian
Schoendube, Daniel
Witzens-Harig, Mathias
Ruckes, Christian
Medler, Christoph
van Oordt, Christina
Klapper, Wolfram
Theobald, Matthias
Dreyling, Martin
HEMASPHERE, 2020, 4 (03):
[2] Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on An Ongoing Phase I/II Trial
Hess, Georg
Keller, Ulrich
Atta, Johannes
Buske, Christian
Borchmann, Peter
Medler, Christoph
Witzens-Harig, Mathias
Dreyling, Martin H.
BLOOD, 2011, 118 (21) : 1159 - 1159
[3] Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on an Ongoing Phase I/II Trial
Hess, Georg
Keller, Ulrich
Atta, Johannes
Bitz, Ulrich
Lerchenmueller, Christian
Karola, Wagner
Medler, Christoph
Ruckes, Christian
Witzens-Harig, Mathias
Huebel, Kai
LaRosee, Paul
Dreyling, Martin H.
BLOOD, 2015, 126 (23)
[4] Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma
G Hess
U Keller
C W Scholz
M Witzens-Harig
J Atta
C Buske
S Kirschey
C Ruckes
C Medler
C van Oordt
W Klapper
M Theobald
M Dreyling
Leukemia, 2015, 29 : 1695 - 1701
[5] Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma
Hess, G.
Keller, U.
Scholz, C. W.
Witzens-Harig, M.
Atta, J.
Buske, C.
Kirschey, S.
Ruckes, C.
Medler, C.
van Oordt, C.
Klapper, W.
Theobald, M.
Dreyling, M.
LEUKEMIA, 2015, 29 (08) : 1695 - 1701
[6] Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-hodgkin's lymphoma
van der Jagt, Richard H.
Cohen, Philip
Cheson, Bruce
Tulpule, Anil
Herst, Jordan A.
Lemieux, Bernard
Schwartzberg, Lee S.
Robinson, K. Sue
Oliver, Jennifer W.
Williams, Michael E.
CANCER INVESTIGATION, 2007, 25 : 35 - 36
[7] A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
Nobuhiko Nakamura
Senji Kasahara
Junichi Kitagawa
Hiroshi Nakamura
Michio Sawada
Kenji Fukuno
Yuhei Shibata
Yuto Kaneda
Takeshi Hara
Nobuhiro Kanemura
Hisashi Tsurumi
Masahito Shimizu
Experimental Hematology & Oncology, 11
[8] A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
Nakamura, Nobuhiko
Kasahara, Senji
Kitagawa, Junichi
Nakamura, Hiroshi
Sawada, Michio
Fukuno, Kenji
Shibata, Yuhei
Kaneda, Yuto
Hara, Takeshi
Kanemura, Nobuhiro
Tsurumi, Hisashi
Shimizu, Masahito
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
[9] Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkin's lymphoma.
Van der Jagt, Richard H.
Cohen, Philip
Cheson, Bruce D.
Tulpule, Anil
Herst, Jordan A.
Lemieux, Bernard
Schwartzberg, Lee S.
Robinson, Katherine Sue
Oliver, Jennifer W.
Williams, Michael E.
BLOOD, 2006, 108 (11) : 766A - 766A
[10] A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
Wang, Luhua
Fayad, Luis
Hagemeister, Fredrick B.
Neelapu, Sattva
Samaniego, Felipe
McLaughlin, Peter
Samuels, Barry
Yi, Qing
Pro, Barbara
Fanale, Michelle
Shah, Jatin
Younes, Anas
Bell, Neda
Knight, Robert
Zeldis, Jerome B.
Cabanillas, Fernando
Kwak, Larry
Romaguera, Jorge
BLOOD, 2009, 114 (22) : 1064 - 1065

← 1 2 3 4 5 →